Development of early-stage clinical and pre-clinical assets:

Neurolixis is developing a platform of early-stage drug candidates targeting serious CNS diseases with unmet medical needs and sizeable market opportunity. Compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism" which enables drugs to more precisely target specific brain regions controlling CNS disorders.

NLX-112, is undergoing a Phase 2A study for the treatment of movement disorders, notably L-DOPA-induced dyskinesia, a side-effect of Parkinson's disease treatment.

NLX-101, is a Phase I drug intended for treatment of autism spectrum disorders such as Rett's syndrome and Fragile X syndrome, serious genetically-encoded orphan disorders. 

NLX-204 is the lead novel chemical entity from the drug discovery program. It is a candidate for development as a potential rapid-acting antidepressant or analgesic (non-opioid mechanism).



All drugs or therapies will be subjected to rigorous testing under applicable law and approval by regulatory authorities, including the FDA, prior to marketing and sale.


Please enable the javascript to submit this form

Follow Neurolixis on: